Evotec
Elisabetta Longo is a seasoned professional in operations and business analysis, currently serving as a Principal Ops Strategic Business Analyst at Evotec since January 2022, previously holding the position of Senior Ops Strategic Business Analyst. Elisabetta's expertise lies in data gathering, analysis, and providing strategic recommendations within the drug development sector. Prior to Evotec, experience included roles as a BI Analyst at Trueblue, focusing on SQL development and data integration, and consultant positions at SDG Group Italy. Elisabetta’s academic background features a Master of Science in Health Data Science from Swansea University, complemented by a Master's and Bachelor's degree in Economics and Business from Università degli Studi di Verona. Notably, a thesis earned recognition and publication in The Lancet.
Previous companies
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.